[Osteoporosis and RANKL signal].

Abstract

Osteoporosis is caused by imbalance between osteoclastic bone resorption and osteoblastic bone formation. From the recent results of several kinds of knockout mice, osteoclast differentiation factor (RANKL) and its soluble decoy receptor for RANKL (OPG) are essentially involved in pathogenesis of osteoporosis. Deficiency of RANKL in human has been shown to result in osteopetrosis. Furthermore, it has been reported that anti-RANKL neutralizing antibody (denosumab) will be effective new drug for osteoporosis.

• Authors: Midori Nakamura, Nobuyuki Udagawa
• Journal: Clinical calcium (Clin Calcium) Vol. 21 Issue 8 Pg. 1149-55 (Aug 2011) ISSN: 0917-5857 [Print] Japan
• PMID: 21814019 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Osteoprotegerin
• RANK Ligand
• Denosumab

Topics

• Animals
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bone Resorption (genetics)
• Cell Differentiation (genetics)
• Denosumab
• Drug Design
• Humans
• Mice
• Molecular Targeted Therapy
• Mutation
• Osteoblasts
• Osteoclasts (cytology)
• Osteopetrosis (genetics)
• Osteoporosis (drug therapy, genetics)
• Osteoprotegerin (physiology)
• RANK Ligand (genetics, immunology, physiology)
• Signal Transduction (physiology)